Acrivastine
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB09488 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 17 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | allergic urticaria | KG + DL |
| 2 | cold urticaria | KG + DL |
| 3 | nasal cavity disease | KG + DL |
| 4 | acute laryngopharyngitis | KG + DL |
| 5 | recalcitrant atopic dermatitis | KG + DL |
| 6 | IgE responsiveness, atopic | KG + DL |
| 7 | rosacea conjunctivitis | KG + DL |
| 8 | faucial diphtheria | KG + DL |
| 9 | trigeminal autonomic cephalalgia | KG + DL |
| 10 | cervical disc degenerative disorder | KG + DL |
| 11 | headache disorder | KG + DL |
| 12 | bronchial disease | KG + DL |
| 13 | endobronchial leiomyoma | KG + DL |
| 14 | endobronchial lipoma | KG + DL |
| 15 | bronchus adenoma | KG + DL |
| 16 | anorectal stricture | KG + DL |
| 17 | autoimmune urticaria | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.